Clinical trials: BCG
Bladder Cancer
URO-BCG-4 : Bladder Tumors Immunotherapy
Evaluation of maintenance BCG immunotherapy (dose 27 mg) in superficial bladder tumors. Two randomized arms (every 3 or 6 months) will be studied for a population of 300 patients.
- Trial name
- NCT00213655
- Testing
- bladder tumor recurrence
- Where
- France
- Volunteers
- 146 people
- Sponsor
- University Hospital, Rouen
Bladder Cancer
Surgery and BCG in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00002990
- Testing
- BCG vaccine
- Where
- 40 sites in Austria, Belgium and 9 more
- Volunteers
- 1,288 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Safety, Immunogenicity
EMaBS TB Vaccine Study
The study will commence with a dose-escalation and age de-escalation study in healthy adults and adolescents from the previous Entebbe Mother and Baby Study (EMaBS) in Entebbe, Uganda, focusing on ChAdOx1 85A, to provide safety…
- Trial name
- NCT03681860
- Testing
- ChAdOx185A, MVA85A, BCG
- Where
- 2 sites in Uganda, United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Neuroblastoma, Sarcoma
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells.
- Trial name
- NCT00003023
- Testing
- BCG vaccine, monoclonal antibody A1G4 anti-idiotype vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mortality, Morbidity
Vitamin A With BCG Vaccine
Two studies from Asia have suggested a beneficial effect of vitamin A supplementation given at birth. Hypotheses: Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in…
- Trial name
- NCT00168597
- Testing
- Vitamin A
- Where
- Guinea-Bissau
- Volunteers
- 4,800 people
- Sponsor
- Bandim Health Project
Tuberculosis
Study of AERAS-402 in Healthy Infants
AERAS-402 will be given to infants of at least 16 weeks of age who have already been vaccinated with BCG to determine if AERAS-402 will increase protection of infants to tuberculosis.
- Trial name
- NCT01198366
- Testing
- AERAS-402 1.5 x 10^10 vp, AERAS-402 3.0 x 10^10 vp, AERAS-402 1.0 x 10^11 vp
- Where
- 7 sites in Kenya, Mozambique and 1 more
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- Aeras
Tuberculosis
Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent
The purpose of this study is to evaluate safety, immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in BCG-vaccinated QFT-negative healthy adolescent.
- Trial name
- NCT03806699
- Testing
- ID93+GLA-SE
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
Tuberculosis
Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon
Filarial nematodes modulate the host immune response to promote regulatory and T helper type 2 immune responses, which were shown to influence concomitant infections.
- Trial name
- MAP-TB (NCT04547738)
- Testing
- TB treatment according to national guidelines
- Where
- Cameroon
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Healthy
Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin
Development of a safe and effective vaccine against leishmaniasis started more than 10 years ago under WHO/TDR supervision. An autoclaved L. major vaccine (ALM) mixed with BCG has been tested in human in Iran, Pakistan and Sudan.
- Trial name
- NCT00429715
- Testing
- Alum-ALM + BCG
- Where
- Iran
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Tuberculosis
Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients
A total of 60 TB patients aged 65 years and below who are randomly assigned to the experimental group and the control group. The experimental group is injected with BCG-PPD test drug once, and the control group is injected with…
- Trial name
- NCT04538911
- Testing
- BCG-PPD
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Diabetes Mellitus, Type 1 Diabetes
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect in new onset pediatric Type 1 diabetes.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
- Trial name
- NCT05866536
- Testing
- Bacillus Calmette-Guérin, Saline Injection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Tuberculosis Infection, Tuberculosis
BCG Revaccination in Children and Adolescents
Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection.
- Trial name
- BRiC (NCT05330884)
- Testing
- BCG vaccine, Oral Chemoprophylaxis
- Where
- India
- Volunteers
- 9,200 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Research Centre, India
Asthma, Eczema
Bacille Calmette-Guérin (BCG) Vaccine and Atopy
The prevalence of asthma and allergic diseases is increasing worldwide. Infections and vaccinations in childhood may have an impact on the subsequent development of asthma and allergy.
- Conditions
- Asthma, Eczema, Food Hypersensitivity
- Trial name
- NCT01420705
- Where
- Guinea-Bissau
- Volunteers
- 487 people
- Sponsor
- Bandim Health Project
Infant Mortality, BCG
Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial
The purpose of this study is to determine whether BCG vaccination shortly after birth can reduce early infant mortality in a rural and an urban setting.
- Trial name
- BCGR (NCT02504203)
- Testing
- BCG-Denmark 1331 (Statens Serum Institute)
- Where
- Guinea-Bissau
- Volunteers
- 2,332 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
TB
Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines
This study is preliminary to proving that this vaccine could protect against tuberculosis in humans. Although there is no proven data to show that infants will benefit directly from participation in this study by being protected…
- Trial name
- NCT00480454
- Testing
- MVA 85A
- Where
- The Gambia
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Early Neonatal Mortality
A Randomized Trial of Providing BCG Vaccination Immediately
Recent studies show that BCG vaccination reduces neonatal mortality by more than 40%. This effect cannot be explained by prevention of tuberculosis, which is very rare among infants.
- Trial name
- NCT01989026
- Testing
- BCG
- Where
- Guinea-Bissau
- Volunteers
- 3,361 people
- Sponsor
- Bandim Health Project
Urinary Bladder Cancer, Urinary Bladder Neoplasm
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder). In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to…
- Conditions
- Urinary Bladder Cancer, Urinary Bladder Neoplasm, BCG, Trans Urethral Resection of a Bladder Tumor
- Trial name
- NCT05946369
- Testing
- Neutrophil to lymphocyte ratio
- Where
- Egypt
- Volunteers
- 96 people
- Sponsor
- Ain Shams University
LTBI, BCG Vaccination Reaction
Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)
TB-reactive immune cells will be tested in a multiparametric flow cytometry to distinguish an immune response for antigens of Mycobacterium spp. in TB disease/latent infection or a reaction after BCG vaccine.
- Conditions
- LTBI, BCG Vaccination Reaction, TB
- Trial name
- NCT04673227
- Testing
- Blood draw
- Where
- 2 sites in Czechia
- Volunteers
- 120 people
- Sponsor
- Thomayer University Hospital
BCG Vaccination Reaction, Tuberculosis
A Study of GC3107(BCG Vaccine) in Healthy Infants
The purpose of this study is to investigate the efficacy and safety of GC3107 in healthy infants
- Trial name
- NCT03947138
- Testing
- GC3107, Intradermal BCG SSI inj.
- Where
- 2 sites in South Korea
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Bladder Cancer
BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop tumor cells from growing.
- Trial name
- NCT00023842
- Testing
- BCG vaccine, mitomycin C, adjuvant therapy
- Where
- 16 sites in Belgium, Italy and 4 more
- Volunteers
- 97 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC